Patrick Flume to Microbial Sensitivity Tests
This is a "connection" page, showing publications Patrick Flume has written about Microbial Sensitivity Tests.
Connection Strength
0.724
-
Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program. Am J Respir Crit Care Med. 2020 01 01; 201(1):114-116.
Score: 0.157
-
Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2020 05; 19(3):370-375.
Score: 0.155
-
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J Cyst Fibros. 2019 03; 18(2):236-243.
Score: 0.147
-
Antimicrobial resistance in cystic fibrosis: Does it matter? J Cyst Fibros. 2018 11; 17(6):687-689.
Score: 0.144
-
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis. 2019 10 30; 69(10):1812-1816.
Score: 0.039
-
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr; 51(4):372-8.
Score: 0.030
-
Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7.
Score: 0.027
-
A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy. 1999 May; 19(5):620-6.
Score: 0.009
-
Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method. Antimicrob Agents Chemother. 1997 Nov; 41(11):2527-32.
Score: 0.008
-
In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 1997 Sep; 41(9):2053-6.
Score: 0.008